Current Status of Olaparib Treatment Based on the Japanese Electronic Medical Record Database
Cancer Treatment and Research Communications · 2026-11 · 101535
DOI: 10.1016/j.ctarc.2026.101535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Masaaki Kawai und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Olaparib is widely used to treat breast and ovarian cancers; however, real-world safety data remain limited. This study aimed to assess the clinical use and adverse events of olaparib in breast and ovarian cancers in Japan. Material and Methods We analyzed big data from the DATuM IDEA® electronic medical records and claims data from 1,539,946 individuals collected by the Japan Medical Association Medical Information Management Organization. Among them, 94 patients with breast cancer and 466 patients with ovarian cancer treated with olaparib were included in the study. Real-world treatment patterns and adverse events in breast cancer were assessed and compared to those with ovarian cancer.
Results
Median ages were 51.5 years for breast cancer and 63.0 years for ovarian cancer, with median treatment durations of 336.0 and 395.5 days, respectively. Grade 3+4 hematologic toxicities, including neutropenia (17.2%), thrombocytopenia (1.1%), and anemia (22.6%), were less frequent in patients with breast cancer than in those with ovarian cancer. Blood transfusions were required in 12.8% of patients with breast cancer and were significantly associated with age ≥65 years [hazard ratio (HR) = 1.91, 95% confidence interval (CI): 1.12–3.25; p = 0.017] and serum creatinine >0.79 mg/dL (HR = 2.12, 95% CI: 1.17–3.86; p = 0.014). Nausea and vomiting occurred in 16.0% of patients with breast cancer, and antiemetics were prescribed to 66.0%.
Conclusions
In routine practice, careful monitoring for anemia is warranted, particularly in older patients and those with mild renal dysfunction during olaparib treatment.
Zitieren
APA
Kawai, M., Kazato, T., Kiyosaki, W., Matsumoto, K., Tanaka, T., & Motoi, F. (2026). Current Status of Olaparib Treatment Based on the Japanese Electronic Medical Record Database. Cancer Treatment and Research Communications, 101535. https://doi.org/10.1016/j.ctarc.2026.101535
Vancouver
Kawai M, Kazato T, Kiyosaki W, Matsumoto K, Tanaka T, Motoi F. Current Status of Olaparib Treatment Based on the Japanese Electronic Medical Record Database. Cancer Treatment and Research Communications. 2026:101535. doi:10.1016/j.ctarc.2026.101535
BibTeX
@article{Kawai2026,
author = {Kawai, Masaaki and Kazato, Tomoko and Kiyosaki, Wakana and Matsumoto, Kei and Tanaka, Takayuki and Motoi, Fuyuhiko},
title = {Current Status of Olaparib Treatment Based on the Japanese Electronic Medical Record Database},
journal = {Cancer Treatment and Research Communications},
year = {2026},
pages = {101535},
doi = {10.1016/j.ctarc.2026.101535}
}
EUVIMED